4 followers
The CARE-MS-II study showed a significant delay in disease progression by alemtuzumab. #MultipleSclerosis http://t.co/SbeoOwPL33
The CARE-MS-II study showed a significant delay in disease progression by alemtuzumab. #MultipleSclerosis http://t.co/SbeoOwPL33